Key Takeaways & Executive Findings
- •• PSRC1 expression is downregulated during macrophage pyroptosis, and its knockout exacerbates pyroptosis and inflammation. • Overexpression of PSRC1 alleviates pyroptosis and inflammation in bone marrow-derived macrophages. • PSRC1 negatively regulates the ECM component periostin (POSTN), and knockdown of POSTN suppresses pyroptosis in PSRC1-deficient macrophages. • This study identifies PSRC1 as a potential therapeutic target for inflammatory diseases involving macrophage pyroptosis.
Abstract
Pyroptosis is a regulated inflammatory cell death process that plays an essential role in various diseases. This study investigates the role of proline/serine-rich coiled-coil protein 1 (PSRC1) in pyroptosis and inflammation in macrophages. This study reports that PSRC1 expression is decreased in pyroptotic macrophages and that knockout of PSRC1 exacerbates pyroptosis and inflammation. PSRC1 overexpression alleviates pyroptosis and inflammation in macrophages. RNA-seq analysis reveals that PSRC1 regulates the expression of genes involved in the extracellular matrix (ECM). Specifically, PSRC1 downregulates the expression of periostin (POSTN), an ECM component. Knockdown of POSTN suppresses macrophage pyroptosis mediated by low expression of PSRC1. These findings suggest that PSRC1 can alleviate pyroptosis and inflammation in bone marrow-derived macrophages (BMDMs) by regulating the ECM and negatively regulating POSTN. This study provides insights into the role of PSRC1 in macrophage pyroptosis and identifies a potential target for the treatment of inflammatory diseases. Further research is needed to confirm these findings in vivo and in various disease models.
1. Introduction
Pyroptosis is a form of regulated inflammatory cell death that involves the cleavage of gasdermin proteins [1]. Upon stimulation of macrophages with pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), inflammasomes such as NLRP3 and ASC are activated [2]. The activated inflammasome binds to Caspase-1 or Caspase-11 (or human Caspase-4/-5) and facilitates its activation through cleavage. Cleaved caspases trigger the cleavage of gasdermin-D (GSDMD) into GSDMD-C and GSDMD-N, with GSDMD-N subsequently forming membrane pores [1]. Caspases also promote the maturation and cleavage of IL-1β and IL-18, which are released through GSDMD-N pores. This process leads to cell swelling and the release of additional intracellular proinflammatory cytokines [3]. Pyroptosis is also known to play a significant role in the pathology of numerous diseases, such as atherosclerosis, Alzheimer′s disease, inflammatory bowel disease and various infectious diseases [4–7]. The identification of molecules involved in pyroptosis is crucial for understanding its mechanisms.
Proline/serine-rich coiled-coil protein 1 (PSRC1), also known as DDA3, belongs to the microtubule-associated protein (MAP) family [8,9]. MAPs play various roles within cells, including signal transduction, metabolic regulation, and material transport [10–12]. Genome-wide association studies (GWASs) have also highlighted the strong association between PSRC1 and coronary artery disease (CAD) [13]. Additionally, our previous study revealed that PSRC1 decreased the phosphorylation of NF-κB and inhibited the release of IL-1β, IL-6, and TNF-α in macrophages [14]. Another study revealed that PSRC1 alleviates atherosclerosis and inhibits inflammation by binding to Annexin A2 (ANXA2) in macrophages [15]. Pyroptosis is a form of regulated inflammatory cell death, but whether PSRC1 alleviates macrophage inflammation via pyroptosis remains unexplored. Taken together, the impact and mechanism of PSRC1 on macrophage pyroptosis have yet to be determined.
Periostin (POSTN) is a matricellular protein of the ECM [16]. The ECM acts as a PAMP or DAMP, stimulating pyroptosis [17]. Several studies have indicated the involvement of POSTN in inflammatory responses. POSTN also aggravated Caspase-1-mediated pyroptosis [18]. In this study, we aimed to investigate the role of PSRC1 in macrophage pyroptosis. We showed that the expression of PSRC1 is downregulated in the process of macrophage pyroptosis. By generating PSRC1-knockout bone marrow-derived macrophages (BMDMs), we further found that PSRC1 mitigates macrophage pyroptosis and the accompanying proinflammatory cytokines. Pyroptosis and inflammatory responses are aggravated in PSRC1-deficient BMDMs. In contrast, overexpression of PSRC1 ameliorates pyroptosis. Through RNA-seq analysis and experimental validation, we further revealed that POSTN mediates this effect and that aggravated pyroptosis can be counteracted by downregulating the expression of POSTN. For the first time, we report that PSRC1 downregulates the expression of POSTN, thereby inhibiting macrophage pyroptosis. This work identifies a novel target for modulating pyroptosis in macrophages and reveals a potential mechanism contributing to the pathogenesis of inflammatory diseases.
Loading authentic research manuscript (Pages 1–5)...
Qiao Wu, Qianqian Wang, Kexin Hu, Tiantian Luo, Jichen Liu, Yazhi Xue, Ling Li, Cuiqi Yang, Rongzhan Lin, Hangyu Pan, Jinhao Wang, Zhigang Guo (2026). Proline/serine-rich coiled-coil protein 1 alleviates pyroptosis in murine bone marrow-derived macrophages. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025012
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the role of PSRC1 in macrophage pyroptosis?
PSRC1 alleviates pyroptosis in bone marrow-derived macrophages by downregulating the expression of periostin (POSTN), an extracellular matrix component, thereby reducing inflammation.
How does PSRC1 affect inflammation in macrophages?
PSRC1 overexpression reduces pyroptosis and the release of proinflammatory cytokines, while its knockout exacerbates these responses, indicating a protective role against inflammation.
What is the significance of POSTN in this study?
POSTN is identified as a downstream mediator of PSRC1; knockdown of POSTN suppresses pyroptosis in PSRC1-deficient macrophages, suggesting that PSRC1 inhibits pyroptosis by negatively regulating POSTN.
What are the potential therapeutic implications of this research?
The findings suggest that PSRC1 could be a novel target for treating inflammatory diseases where macrophage pyroptosis plays a role, such as atherosclerosis and other chronic inflammatory conditions.
What methods were used in this study?
The study used bone marrow-derived macrophages from mice, generated PSRC1 knockout and overexpression models, performed RNA-seq analysis, and validated findings with experimental assays to assess pyroptosis and inflammation.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.